文献速递认知障碍与谵妄多重用药

入住养老院时抗痴呆药物变化:谁决定及为何?全国养老院管理者调查结果

Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.
PubMed 文献 · J Am Med Dir Assoc · 2023-10-28

该研究于2022年调查美国1293家养老院(应答率26.6%,n=340),加权分析代表14455家。护理主任报告,养老院处方者(84.4%)最常参与抗痴呆药物决策,而居民(13.8%)和家庭(23.4%)参与较少;居民和家庭意愿、痴呆专家参与及行为症状影响药物启用与停用。

要点

  • 养老院处方者几乎总是参与抗痴呆药物决策(84.4%),居民和家庭参与率较低。
  • 居民(55.8%)和家庭(53.2%)希望用药时,抗痴呆药物更可能被启用。
  • 痴呆专家参与(46.5%)和进展至重度损害(39.2%)时,药物更可能被停用。

核心结论

  • 护理主任报告家庭/照护者和痴呆专家对养老院抗痴呆药物决策有显著影响,但许多居民缺乏这些参与。
  • 需要真实世界证据来指导养老院抗痴呆药物的适当使用。

研究设计与样本

  • 全国养老院调查,调查≥30床位的养老院,对痴呆单元养老院过度抽样。
  • 2022年调查1293家养老院,应答率26.6%(n=340),加权分析代表14455家。

主要发现

  • 几乎总是参与抗痴呆药物决策的人员:养老院处方者84.4%、护理人员33.2%、家庭23.4%、居民13.8%、社区初级保健提供者12.1%、痴呆专家5.8%。
  • 抗痴呆药物更可能被启用的因素:居民希望用药55.8%、家庭成员希望用药53.2%、痴呆专家参与51.9%、居民有攻击行为44.8%、抗拒照护31.6%、严重躯体/认知损害22.3%。
  • 抗痴呆药物更可能被停用的因素:痴呆专家参与46.5%、进展至重度损害39.2%、安宁疗护参与31.5%、预后<6个月28.5%、出现攻击行为25.2%、抗拒照护19.0%。
  • 抗痴呆药物更不可能被停用的因素:居民不愿停药30.2%、家庭不愿停药27.3%。
  • 六分之一养老院报告居民通常或几乎总是没有直系亲属/照护者。

临床怎么用

  • 临床决策抗痴呆药物时,应评估居民和家庭意愿,并考虑痴呆专家参与。
  • 关注攻击行为、抗拒照护、严重损害和安宁疗护等影响药物启用或停用的因素。
  • 识别缺乏家庭/照护者参与的居民,确保决策支持。

局限性

  • 应答率26.6%,可能存在无应答偏倚。
  • 结果为护理主任报告,非直接临床观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Little is known about who is involved and what factors influence changes in antidementia medications for older adults living in nursing homes. The study sought to describe factors associated with initiation and discontinuation of antidementia medications in nursing home residents with dementia. DESIGN: National survey of nursing homes with ≥30 beds; homes with dementia units were oversampled. SETTINGS AND PARTICIPANTS: Nursing home administrators [eg, Directors of Nursing (DoNs)]. METHODS: In 2022, 1293 homes were surveyed (response rate: 26.6%, n = 340). Weighted analyses provided nationally representative results corrected for nonresponse (n = 14,455). RESULTS: DoNs reported that people always/almost always involved in antidementia medication decisions included nursing home prescriber (84.4%), nursing staff (33.2%), family (23.4%), resident (13.8%), community primary care provider (12.1%), and dementia specialist (5.8%). DoNs reported that antidementia medications were much more likely to be initiated if residents (55.8%) and family members (53.2%) wanted antidementia medications, a dementia specialist was involved (51.9%), resident had aggressive behaviors (44.8%), resisted care (31.6%), or had severe physical/cognitive impairment (22.3%). DoNs reported that antidementia medications were much more likely to be discontinued with dementia specialist involvement (46.5%), progression to severe impairment (39.2%), hospice involvement (31.5%), <6 months' prognosis (28.5%), emergence of aggressive behaviors (25.2%), or resisting care (19.0%) and much less likely to be discontinued if residents (30.2%) and family (27.3%) were reluctant to discontinue. One in 6 homes reported that residents had no immediate family/caregivers usually or almost always/always. CONCLUSIONS AND IMPLICATIONS: DoNs report that family/caregivers and dementia specialists have significant influence on antidementia medication decisions in nursing homes, but many residents lack their involvement. Real-world evidence on the risks and benefits of antidementia medications in nursing homes is needed to inform clinical guidance about appropriate use of antidementia medications in nursing homes.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Lapane KL, Ott BR, Hargraves JL, et al. Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators. J Am Med Dir Assoc. 2023. PMID: 38173265. doi:10.1016/j.jamda.2023.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。